Sirona Biochem (Sirona Biochem) EBIT : $-1.77 Mil (TTM As of Jan. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Sirona Biochem EBIT?

Sirona Biochem's earnings before interest and taxes (EBIT) for the three months ended in Jan. 2024 was $-0.50 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jan. 2024 was $-1.77 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sirona Biochem's annualized ROC % for the quarter that ended in Jan. 2024 was -370.76%. Sirona Biochem's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2024 was -33,000.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sirona Biochem's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2024 was -14.91%.

Sirona Biochem EBIT Historical Data

The historical data trend for Sirona Biochem's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sirona Biochem EBIT Chart

Sirona Biochem Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

EBIT

Get a 7-Day Free Trial

-3.37

-3.12

-1.86

-2.58

-1.71

Sirona Biochem Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EBIT	Get a 7-Day Free Trial															-0.46	-0.56	-0.34	-0.37	-0.50

Competitive Comparison of Sirona Biochem's EBIT

For the Biotechnology subindustry, Sirona Biochem's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sirona Biochem's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sirona Biochem's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sirona Biochem's EV-to-EBIT falls into.

Sirona Biochem EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.77 Mil.

Sirona Biochem (OTCPK:SRBCF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sirona Biochem's annualized ROC % for the quarter that ended in Jan. 2024 is calculated as:

	ROC % (Q: Jan. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Oct. 2023 )	+	Invested Capital (Q: Jan. 2024 ))	/ count )
=	-1.98 * ( 1 - -0.18% )	/	( (0.477	+	0.593)	/ 2 )
=	-1.983564	/	0.535
=	-370.76 %

where

	Invested Capital		(Q: Oct. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.753	-	0.892	-	( 0.416	-	max(0, 1.362	-	0.746	+	0.416	))
=	0.477

	Invested Capital		(Q: Jan. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.522	-	0.751	-	( 0.083	-	max(0, 1.339	-	0.517	+	0.083	))
=	0.593

Note: The Operating Income data used here is four times the quarterly (Jan. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Sirona Biochem's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jan. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Oct. 2023		Q: Jan. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.98	/	( ( (0.007 + max(-0.881, 0))	+	(0.005 + max(-0.724, 0)) )	/	2 )
=	-1.98	/	( ( 0.007	+	0.005 )	/	2 )
=	-1.98	/	0.006
=	-33,000.00 %

where Working Capital is:

	Working Capital		(Q: Oct. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.005	+	0	+	0.006)	-	(0.892	+	0	+	0)
=	-0.881

	Working Capital		(Q: Jan. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.002	+	0	+	0.024)	-	(0.751	+	0	+	-0.00099999999999989)
=	-0.724

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jan. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sirona Biochem's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jan. 2024 )
	=	-1.772	/	11.887
	=	-14.91 %

Sirona Biochem EBIT Related Terms

Thank you for viewing the detailed overview of Sirona Biochem's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Sirona Biochem (Sirona Biochem) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sirona Biochem Corp (OTCPK:SRBCF) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

ZSB:Germany SBM:Canada

Address

C/o WeWork, 595 Burrard Street, Vancouver, BC, CAN, V7X 1L3

Website

https://www.sironabiochem.com

Sirona Biochem Corp is a development stage biotechnology company. The principal activities of the company are the development of cosmetic and pharmaceutical active ingredients which are licensed to partners in exchange for upfront, milestone, and royalty payments. The company acts as a cosmetic ingredient and drug discovery company with a proprietary technology platform with a specialization in the stabilization of carbohydrate molecules. It has a business presence in Canada and France.